# Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

> **NCT05110209** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 331541 (actual)

## Conditions studied

- Age-related Macular Degeneration (AMD)

## Interventions

- **OTHER:** Aflibercept
- **OTHER:** Ranibizumab
- **OTHER:** Bevacizumab

## Key facts

- **NCT ID:** NCT05110209
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-15
- **Primary completion:** 2020-11-20
- **Final completion:** 2020-11-20
- **Target enrollment:** 331541 (ACTUAL)
- **Last updated:** 2021-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05110209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05110209, "Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05110209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*